Abstract:N 6 -methyladenosine (m 6 A) RNA modification is a reversible mechanism that regulates eukaryotic gene expression. Growing evidence has demonstrated an association between m 6 A modification and tumorigenesis and response to immunotherapy. However, the overall influence of m 6 A regulators on the tumor microenvironment and their effect on the response to immunotherapy in lung adenocarcinoma remains to be explored. Here, we comprehensively analyzed the m 6 A modification patterns of 936 lung adenocarcinoma samples based on 24 m 6 A regulators. First, we described the features of genetic variation in these m 6 A regulators. Many m 6 A regulators were aberrantly expressed in tumors and negatively correlated with most tumor-infiltrating immune cell types. Furthermore, we identified three m 6 A modification patterns using a consensus clustering method. m 6 A cluster B was preferentially associated with a favorable prognosis and enriched in metabolism-associated pathways. In contrast, m 6 A cluster A was associated with the worst prognosis and was enriched in the process of DNA repair. m 6 A cluster C was characterized by activation of the immune system and a higher stromal cell score. Surprisingly, patients who received radiotherapy had a better prognosis than patients without radiotherapy only in the m 6 A cluster C group. Subsequently, we constructed an m 6 A score model that qualified the m 6 A modification level of individual samples by using principal component analysis algorithms. Patients with high m 6 A score were characterized by enhanced immune cell infiltration and prolonged survival time and were associated with lower tumor mutation burden and PD-1/CTLA4 expression. The combination of the m 6 A score and tumor mutation burden could accurately predict the prognosis of patients with lung adenocarcinoma. Furthermore, patients with high m 6 A score exhibited greater prognostic benefits from radiotherapy and immunotherapy. This study demonstrates that m 6 A modification is significantly associated with tumor microenvironment diversity and prognosis. A comprehensive evaluation of m 6 A modification patterns in single tumors will expand our understanding of the tumor immune landscape. In addition, our m 6 A score model demonstrated that the level of immune cell infiltration plays a significant role in cancer immunotherapy and provides a basis to increase the efficiency of current immune therapies and promote the clinical success of immunotherapy.

Molecular Characterization and Clinical Relevance of m6A Regulators in Metastatic Prostate Cancer

Molecular Characterization and Clinical Relevance of N6-Methyladenosine Regulators in Metastatic Prostate Cancer

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

Comprehensive analysis of m6A regulators prognostic value in prostate cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

M6a Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer

The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma

The m6A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma

RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations

Systematic Investigation of Mrna N 6-Methyladenosine Machinery in Primary Prostate Cancer.

Expression and Prognostic Characteristics of m6A RNA Methylation Regulators in Colon Cancer

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

RNA M6a Methylation Regulators Multi-Omics Analysis in Prostate Cancer.

Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers

Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma

Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types

Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma

N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer

Molecular Characterization and Clinical Relevance of m6A RNA Methylation Regulators in Cervical Cancer

Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma